Trade Genfit SA - GNFTfr CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.04 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.017952% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | -0.004271% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | EUR | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | France | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.22 |
| Open | 3.27 |
| 1-Year Change | 0.62% |
| Day's Range | 3.23 - 3.37 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 31, 2025 | 3.22 | -0.04 | -1.23% | 3.26 | 3.32 | 3.22 |
| Mar 28, 2025 | 3.31 | 0.06 | 1.85% | 3.25 | 3.43 | 3.25 |
| Mar 27, 2025 | 3.31 | 0.06 | 1.85% | 3.25 | 3.45 | 3.25 |
| Mar 26, 2025 | 3.25 | -0.01 | -0.31% | 3.26 | 3.33 | 3.25 |
| Mar 25, 2025 | 3.32 | 0.04 | 1.22% | 3.28 | 3.38 | 3.28 |
| Mar 24, 2025 | 3.31 | -0.06 | -1.78% | 3.37 | 3.40 | 3.27 |
| Mar 21, 2025 | 3.35 | 0.03 | 0.90% | 3.32 | 3.47 | 3.26 |
| Mar 20, 2025 | 3.31 | 0.02 | 0.61% | 3.29 | 3.36 | 3.28 |
| Mar 19, 2025 | 3.35 | 0.04 | 1.21% | 3.31 | 3.35 | 3.31 |
| Mar 18, 2025 | 3.37 | 0.11 | 3.37% | 3.26 | 3.41 | 3.26 |
| Mar 17, 2025 | 3.33 | 0.03 | 0.91% | 3.30 | 3.33 | 3.25 |
| Mar 14, 2025 | 3.29 | 0.03 | 0.92% | 3.26 | 3.35 | 3.25 |
| Mar 13, 2025 | 3.26 | -0.05 | -1.51% | 3.31 | 3.43 | 3.26 |
| Mar 12, 2025 | 3.30 | 0.00 | 0.00% | 3.30 | 3.42 | 3.30 |
| Mar 11, 2025 | 3.33 | -0.01 | -0.30% | 3.34 | 3.48 | 3.28 |
| Mar 10, 2025 | 3.39 | 0.02 | 0.59% | 3.37 | 3.45 | 3.34 |
| Mar 7, 2025 | 3.44 | 0.05 | 1.47% | 3.39 | 3.45 | 3.35 |
| Mar 6, 2025 | 3.42 | 0.07 | 2.09% | 3.35 | 3.47 | 3.35 |
| Mar 5, 2025 | 3.32 | 0.03 | 0.91% | 3.29 | 3.46 | 3.28 |
| Mar 4, 2025 | 3.27 | -0.12 | -3.54% | 3.39 | 3.45 | 3.27 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Genfit Company profile
About Genfit SA
Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
Financial summary
BRIEF: For the six months ended 30 June 2021, Genfit SA revenues decreased 42% to EUR3.4M. Net income totaled EUR9.1M vs. loss of EUR53M. Revenues reflect Public Financing of research expenditure decrease of 38% to EUR3.2M, Other Operating Income decrease of 66% to EUR174K, Revenue decrease of 91% to EUR11K. Net Income reflects R&D Subcontractors decrease of 38% to EUR15M (expense).
Equity composition
01/2014, Rights Issue, 1 new share for every 33 shares held @ EUR6.98 (Factor: 1.00937).10/2016, Rights Issue, 1 new share for every 9 shares held @ EUR14.3 (Factor: 1.09242).
| Industry: | Biotechnology & Medical Research (NEC) |
Parc Eurasanté 885 avenue Eugène Avinée
LOOS
HAUTS-DE-FRANCE 59120
FR
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com